Funded Biotechnology Startups in Amsterdam
Amsterdam's biotechnology sector shows 12 tracked funding rounds spanning March 2022 through October 2025, with disclosed amounts ranging from $4M to $138M.
Amsterdam's biotechnology sector shows 12 tracked funding rounds spanning March 2022 through October 2025, with disclosed amounts ranging from $4M to $138M. VectorY's $138M Series A in November 2023 is the largest round in the set by a wide margin; the next tier includes Leyden Labs at $35M (October 2025) and Scenic Biotech at $31M (March 2022, also Series A). Seven of the twelve rounds carry a "Series Unknown" classification, which limits stage-level analysis across the cohort.
Activity clustered in Q4 2023: VectorY, RespiQ, and Lapsi Health all closed in November of that year within a ten-day span. The most recent round on record is Leyden Labs' $35M venture deal in October 2025, preceded by two October 2024 closings — LUMICKS at $22M and Confocal.nl at $5M. Seed rounds in this group — Lapsi Health, PayEye, and Xinvento — have been sub-$5M or undisclosed.
Most recent rounds
12 shownRelated listings
Frequently asked
What is the largest disclosed round among Amsterdam biotech startups in this dataset?
VectorY raised $138M in a Series A closed November 13, 2023 — the top disclosed amount in this set by a significant margin. Scenic Biotech's $31M Series A (March 2022) and Leyden Labs' $35M venture round (October 2025) are the next two largest.
How recent is the deal activity shown for Amsterdam biotech companies?
The most recent round is Leyden Labs' $35M venture close on October 4, 2025. Before that, LUMICKS ($22M) and Confocal.nl ($5M) both closed in October 2024, showing continued deal flow through the mid-2020s.
What funding stages are most common among these Amsterdam biotech companies?
Seven of the 12 rounds are classified as "Series Unknown," which limits precise stage tracking. Two are Series A — VectorY and Scenic Biotech — and three are Seed-stage: Lapsi Health, PayEye, and Xinvento.
Did any period see a notable clustering of Amsterdam biotech deals?
November 2023 had three closings within a ten-day window: Lapsi Health ($4M Seed, Nov 10), VectorY ($138M Series A, Nov 13), and RespiQ ($4M, Nov 20). No other month in the dataset shows comparable density.
Are any rounds in this dataset undisclosed?
Two companies did not report round amounts: Genewity B.V., which closed a Series Unknown round in June 2023, and Xinvento, which closed a Seed round in April 2022.
What deal sizes are typical for Amsterdam biotech rounds outside the top outlier?
Excluding VectorY's $138M Series A, most disclosed rounds in this set fall between $4M and $35M. Four companies — RespiQ, Lapsi Health, PayEye, and Scinvivo — each raised $4M or $5M, reflecting a common early-stage funding band.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.